ALKBH5 and urinary bladder carcinoma: In bladder cancer tissues, the low expression of ALKBH5 cannot reduce the m6A modification level of CK2α mRNA, which increases the stability of CK2α mRNA, prolongs its half-life, ultimately accelerates the glycolysis, proliferation, migration and invasion of bladder cancer cells, and reduces the sensitivity of bladder cancer cells to cisplatin chemotherapy [163].